Tyra Biosciences Inc Total Liabilities
Tyra Biosciences Inc total liabilities. Based on the latest financial reports, Tyra Biosciences Inc (TYRA) has total liabilities worth $23.43 Million USD as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check TYRA cash and liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Tyra Biosciences Inc (2019–2025)
Total liabilities of Tyra Biosciences Inc from 2019 to 2025. This chart illustrates how Tyra Biosciences Inc's total liabilities have evolved over time, based on quarterly financial data.
Tyra Biosciences Inc Competitors by Total Liabilities
The table below lists competitors of Tyra Biosciences Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Hoymiles Power Electronics Inc
SHG:688032
|
China | CN¥1.94 Billion |
|
Pabrik Kertas Tjiwi Kimia Tbk
JK:TKIM
|
Indonesia | Rp988.48 Million |
|
Yunnan Hongxiang Yixintang
SHE:002727
|
China | CN¥7.70 Billion |
|
Genting Plantations Bhd
KLSE:2291
|
Malaysia | RM4.01 Billion |
|
PolEnergia S.A.
WAR:PEP
|
Poland | zł4.12 Billion |
|
Dauch Corporation
NYSE:DCH
|
USA | $9.77 Billion |
|
Brighton-Best International Taiwan
TWO:8415
|
Taiwan | NT$17.17 Billion |
|
Netcare
JSE:NTC
|
South Africa | ZAC18.24 Billion |
Liability Composition Analysis (2019–2025)
This chart breaks down Tyra Biosciences Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Tyra Biosciences Inc asset portfolio.
Liquidity & Leverage Metrics
Tyra Biosciences Inc Total Liabilities Ratios Explained
Tyra Biosciences Inc total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 14.67 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.09 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.08 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Tyra Biosciences Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Tyra Biosciences Inc (2019–2025)
The table below shows the annual total liabilities of Tyra Biosciences Inc from 2019 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $23.43 Million | +14.82% |
| 2024-12-31 | $20.41 Million | -5.50% |
| 2023-12-31 | $21.59 Million | +158.56% |
| 2022-12-31 | $8.35 Million | +68.25% |
| 2021-12-31 | $4.96 Million | -83.26% |
| 2020-12-31 | $29.65 Million | +462.71% |
| 2019-12-31 | $5.27 Million | -- |
About Tyra Biosciences Inc
Tyra Biosciences, Inc., a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions. It… Read more